You are here

Comparative systematic genetics for cardiovascular disease gene identification

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HL083571-01A1
Agency Tracking Number: HL083571
Amount: $182,732.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2006
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
OMICIA, INC. 5801 Christie Ave, Suite 500
EMERYVILLE, CA 94608
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JOEL BADER
 (410) 516-7417
 joel.bader@jhu.edu
Business Contact
 MARTIN REESE
Phone: (510) 595-0800
Email: mreese@omicia.com
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): This proposal will lead to identification of gene variants that increase the risk of developing cardiovascular disease. The underlying hypothesis is that systematic genetics conducted in model organisms enables the identification of disease-specific gene modules. This hypothesis will be tested in Phase I through the following Aims: (1) Create a database of phenotypes observed in systematic genetic screens conducted in yeast, worm, fly, zebrafish, and other model organisms. (2) Develop and apply data mining algorithms to identify modules of genes whose deletion or silencing phentoypes show similar patterns across model organisms. (3) Identify modules that are enriched for genes with known variants relevant to cardiovascular disease. Other genes in these modules will then be candidate genes for variants conferring cardiovascular disease risk or can be used to improve priors for whole-genome association tests. In Phase II, variants of candidate genes will be genotyped across a cardiovascular patient population with the goal of identifying genetic markers to assist in diagnosis and treatment of cardiovascular disease. If successful, this proposal will lead to genetic tests that will improve the clinical treatment of patients at risk for cardiovascular disease. The comparative systematic genetics platform developed will be broadly applicable to identifying gene modules relevant to other human diseases and will extend to systematic genetics data collected for a growing set of model organisms.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government